actin related protein 2/3 complex subunit 4Genealiases: ARC20 · DEVLO · P20-ARC
Q-omics provides the consensus-scored ARPC4 profile across patient tissues and cancer cell-line models. ARPC4 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, ARPC4 is differentially expressed in 12, with the highest sampling consensus in LIHC. Additionally, ARPC4 protein abundance shows 24,954 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight UVM, LIHC, and BRCA as cancer lineages where ARPC4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ARPC4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ARPC4 survival associations across molecular data types. ARPC4 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (4) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ARPC4 RNA expression–survival associations across cancer types. High ARPC4 expression shows unfavorable associations in LIHC, KICH, ACC and LGG, but favorable associations in UVM and KIRP. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for ARPC4 RNA expression.
This table summarizes ARPC4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 5. The strongest signals are observed in LIHC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for ARPC4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ARPC4 shows lower tumor expression in KICH and LUSC and higher tumor expression in LIHC, STAD, BRCA and CHOL. The LIHC box plot shows higher ARPC4 RNA expression in tumor versus normal tissue (log2 FC = +1.048, t-test p < 0.001).
This table shows molecular features associated with ARPC4 in patient tissues and cancer cell lines. In patient samples, ARPC4 shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set. In cancer cell lines, ARPC4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Lymphoma.
